<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INDOMETHACIN- indomethacin injection, powder, lyophilized, for solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Indomethacin for Injection safely and effectively. See full prescribing information for Indomethacin for Injection.<br><br>Indomethacin for Injection<br>Initial U.S. Approval: 1965</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Indomethacin for Injection is a cardiovascular drug indicated: </p>
<ul><li>To close a hemodynamically significant <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> in premature infants weighing between 500 and 1,750 g. (<a href="#b7a17772-02dc-4d76-97c1-bd8e61359d1a">1</a>)</li></ul>
<p class="Highlighta">  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul><li>Dosage is dependent on the age of the infant at time of therapy.  A course of therapy requires intravenous doses of Indomethacin for Injection given at 12 to 24 hour intervals.  </li></ul>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">AGE at 1st dose </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="Highlighta">DOSAGE (mg/kg) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
<p class="Highlighta">  </p>
<p class="Highlighta">Less than 48 hours </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="Highlighta">  </p>
<p class="Highlighta">1st </p>
<p class="Highlighta">0.2 </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="Highlighta">  </p>
<p class="Highlighta">2nd </p>
<p class="Highlighta">0.1 </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="Highlighta">  </p>
<p class="Highlighta">3rd </p>
<p class="Highlighta">0.1 </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">2 to 7 days </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.2 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.2 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.2 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">Over 7 days </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.2 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.25 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="Highlighta">0.25 </p></td>
</tr>
</tbody></table>
<ul>
<li>If <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or marked <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> (urinary output &lt;0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose of Indomethacin for Injection, do not give additional doses until laboratory studies indicate that renal function has returned to normal </li>
<li>If the ductus arteriosus closes or is significantly reduced in size after an interval of 48 hours or more from completion of the first course of Indomethacin for Injection, no further doses are necessary </li>
<li>If the neonate remains unresponsive to therapy with Indomethacin for Injection after 2 courses, surgery may be necessary for closure of the ductus arteriosus. (<a href="#fe03c621-9791-480d-9c9e-0a098da45cd9">2.1</a>) </li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Single use vials of 1 mg indomethacin as a sterile, lyophilized powder or plug for reconstitution. (<a href="#ac16b354-ba60-4b46-a883-8b0506b07772">3</a>) </li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Indomethacin for Injection is contraindicated in neonates: </p>
<ul>
<li>With proven or suspected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that is untreated</li>
<li>Who are <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, especially those with active <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span></li>
<li>With <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or coagulation defects</li>
<li>Suspected of having <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span></li>
<li>With significant impairment of renal function</li>
<li>With congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow. (<a href="#e43da573-3fe2-4eb2-85c1-6369501b575b">4</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Indomethacin may mask the usual signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#fdcb819d-609f-4631-a7c5-ebcc28db0718">5.1</a>)</li>
<li>Monitor for signs of hepatic reactions. Indomethacin for Injection may need to be discontinued. (<a href="#b627dc65-dbca-41db-b625-a0604f87de61">5.2</a>)</li>
<li>Indomethacin for Injection may inhibit platelet aggregation. (<a href="#ffb4d13c-2787-4213-95af-1a14dc8f2f7f">5.3</a>)</li>
<li>Gastrointestinal Effects:  Monitor neonates for <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stool</span>. (<a href="#b033b56e-92c7-440f-b27d-7bd2551afbca">5.4</a>)</li>
<li>Central Nervous System Effects: Monitor neonates for <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span>. (<a href="#d9115c25-8dc6-491c-90b9-9f873db4d00e">5.5</a>)</li>
<li>Renal Effects: Monitor renal function and serum electrolytes. (<a href="#e9ad44b0-0146-45c4-95b4-44923778690c">5.6</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems, higher incidence of transient <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and elevations of serum creatinine. (<a href="#dc1585e0-f20b-4c95-b7ec-aa72064369d7">6.1</a>) </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance &amp; Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>When used concomitantly with digoxin, monitor neonates for the development of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. (<a href="#e2a3187c-6d3d-47c0-8e7f-7ad0d607bfa1">7.1</a>)</li>
<li>Monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when indomethacin is added to anticoagulants. (<a href="#c8db1e5f-72fb-4863-87ff-a96f9f0b421b">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Directions for Use<br></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatic Reactions<br></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Platelet Aggregation<br></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Gastrointestinal Effects<br></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Central Nervous System Effects<br></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Renal Effects<br></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Administration<br></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience<br></a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Digoxin<br></a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Anticoagulants<br></a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Furosemide<br></a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Aminoglycosides<br></a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Drugs that Act on the Renin-Angiotensin System<br></a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-9.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h1><a href="#section-11" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-11.1" class="toc">16.1 How Supplied<br></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b7a17772-02dc-4d76-97c1-bd8e61359d1a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Indomethacin for Injection is indicated to close a hemodynamically significant <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.  Clear-cut clinical evidence of a hemodynamically significant <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> should be present, such as <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, a continuous murmur, a <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> precordium, <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, or pulmonary plethora on chest x-ray.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e9aa6fb6-3ad5-401e-8241-e4684bb1f985"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis">For intravenous administration only</span></span>.</p>
<p>Dosage recommendations for closure of the ductus arteriosus depend on the age of the infant at the time of therapy.  A course of therapy is defined as three intravenous doses of Indomethacin for Injection given at 12 to 24 hour intervals, with careful attention to urinary output.  If <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or marked <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> (urinary output &lt;0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose of Indomethacin for Injection, do not give additional doses until laboratory studies indicate that renal function has returned to normal <span class="Italics"><span class="Emphasis">[see <a href="#f2a7c486-3e93-4d65-b602-fd49bd18592c">Warnings and Precautions (5.7)</a>]</span></span>.</p>
<p>Dosage according to age is as follows:</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AGE at 1st dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First">DOSAGE (mg/kg)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"> </p>
<p>Less than 48 hours</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">1st</p>
<p>0.2</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">2nd</p>
<p>0.1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">3rd</p>
<p>0.1</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 to 7 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Over 7 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.25</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.25</p></td>
</tr>
</tbody></table>
<p>If the ductus arteriosus closes or is significantly reduced in size after an interval of 48 hours or more from completion of the first course of Indomethacin for Injection, no further doses are necessary.  If the ductus arteriosus re-opens, a second course of 1 to 3 doses may be given, each dose separated by a 12 to 24 hour interval as described above.</p>
<p>If the neonate remains unresponsive to therapy with Indomethacin for Injection after 2 courses, surgery may be necessary for closure of the ductus arteriosus.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="fe03c621-9791-480d-9c9e-0a098da45cd9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Directions for Use<br>
</h2>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p>
<p>The reconstituted solution, pH 6.0 to 7.5, is clear, slightly yellow and essentially free from visible particles.  </p>
<p>Prepare the solution with 1 to 2 mL of preservative-free Sterile Sodium Chloride Injection, 0.9 percent or preservative-free Sterile Water for Injection.  Benzyl alcohol as a preservative has been associated with toxicity in neonates.  Therefore, do not use diluents that contain preservatives.  If 1 mL of diluent is used, the concentration of indomethacin in the solution will equal approximately 0.1 mg/0.1 mL; if 2 mL of diluent are used, the concentration of the solution will equal approximately 0.05 mg/0.1 mL.  Discard any unused portion of the solution as it does not contain a preservative.  Prepare a fresh solution just prior to each administration.  Once reconstituted, the indomethacin solution may be injected intravenously.  While the optimal rate of injection has not been established, published literature suggests an infusion rate over 20 to 30 minutes.  </p>
<p>Further dilution with intravenous infusion solutions is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ac16b354-ba60-4b46-a883-8b0506b07772"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Indomethacin for Injection is supplied in single use vials containing 1 mg of indomethacin as a sterile lyophilized powder or plug for reconstitution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e43da573-3fe2-4eb2-85c1-6369501b575b"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Indomethacin for Injection is contraindicated in neonates: </p>
<ul>
<li>With proven or suspected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that is untreated</li>
<li>Who are <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, especially those with active <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span></li>
<li>With <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or coagulation defects</li>
<li>With or who are suspected of having <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span></li>
<li>With significant impairment of renal function</li>
<li>With congenital heart disease in whom patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow (e.g., pulmonary atresia, severe <span class="product-label-link" type="condition" conceptid="320835" conceptname="Tetralogy of Fallot">tetralogy of Fallot</span>, severe <span class="product-label-link" type="condition" conceptid="321119" conceptname="Coarctation of aorta">coarctation of the aorta</span>).</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ba503b46-34a3-4f63-91ee-0ab09eb84f10"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="fdcb819d-609f-4631-a7c5-ebcc28db0718"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">Indomethacin may mask the usual signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  Therefore, the physician must be continually on the alert for this and should use the drug with extra care in the presence of existing controlled <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b627dc65-dbca-41db-b625-a0604f87de61"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hepatic Reactions<br>
</h2>
<p class="First">Severe hepatic reactions have been reported in adults treated chronically with oral indomethacin for arthritic disorders.  [For further information, see package insert for oral indomethacin].  If clinical signs and symptoms consistent with liver disease develop in the neonate, or if systemic manifestations occur, discontinue Indomethacin for Injection.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ffb4d13c-2787-4213-95af-1a14dc8f2f7f"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Platelet Aggregation<br>
</h2>
<p class="First">Indomethacin for Injection may inhibit platelet aggregation.  In one small study, platelet aggregation was grossly abnormal after indomethacin therapy (given orally to premature infants to close the ductus arteriosus).  Platelet aggregation returned to normal by the tenth day.  Observe premature infants for signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b033b56e-92c7-440f-b27d-7bd2551afbca"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Gastrointestinal Effects<br>
</h2>
<p class="First">In the collaborative study, major <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> was no more common in neonates receiving indomethacin than in neonates on placebo.  However, minor <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> (i.e., chemical detection of blood in the stool) was more commonly noted in neonates treated with indomethacin.  Severe gastrointestinal effects have been reported in adults with various arthritic disorders treated chronically with oral indomethacin.  [For further information, see package insert for oral indomethacin].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="d9115c25-8dc6-491c-90b9-9f873db4d00e"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Central Nervous System Effects<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span> per se is associated with an increased incidence of spontaneous <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span>.  Because indomethacin may inhibit platelet aggregation, the potential for intraventricular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be increased.  However, in the large multicenter study of Indomethacin for Injection, the incidence of <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span> in neonates treated with Indomethacin for Injection was not significantly higher than in the control neonates.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="e9ad44b0-0146-45c4-95b4-44923778690c"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Renal Effects<br>
</h2>
<p class="First">Indomethacin for Injection may cause significant reduction in urine output (50 percent or more) with concomitant elevations of blood urea nitrogen and creatinine, and reductions in glomerular filtration rate and creatinine clearance.  These effects in most neonates are transient, disappearing with cessation of therapy with Indomethacin for Injection.  However, because adequate renal function can depend upon renal prostaglandin synthesis, Indomethacin for Injection may precipitate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, especially in neonates with other conditions that may adversely affect renal function (e.g., extracellular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> from any cause, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, concomitant use of any nephrotoxic drug, hepatic dysfunction).  When significant suppression of urine volume occurs after a dose of Indomethacin for Injection, do not give additional doses until urine output returns to normal levels.</p>
<p>Indomethacin for Injection in pre-term infants may suppress water excretion to a greater extent than sodium excretion.  When this occurs, a significant reduction in serum sodium values (i.e., <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) may result.  Monitor renal function and serum electrolyte levels during therapy with Indomethacin for Injection  <span class="Italics"><span class="Emphasis">[see <a href="#e9aa6fb6-3ad5-401e-8241-e4684bb1f985">Dosage and Administration (2)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f2a7c486-3e93-4d65-b602-fd49bd18592c"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Administration<br>
</h2>
<p class="First">Administer Indomethacin for Injection carefully to avoid extravascular injection or leakage as the solution may be irritating to tissue.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="aecaf11d-097e-42f4-9a67-36e473a6e0a7"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="dc1585e0-f20b-4c95-b7ec-aa72064369d7"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience<br>
</h2>
<p class="First">In a double-blind, placebo-controlled trial of 405 premature infants weighing less than or equal to 1,750 g with evidence of large ductal shunting, in those neonates treated with indomethacin (n=206), there was a statistically significantly greater incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems, including gross or microscopic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> into the gastrointestinal tract, oozing from the skin after needle stick, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, and disseminated intravascular <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>.  There was no statistically significant difference between treatment groups in <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.</p>
<p>The neonates treated with Indomethacin for Injection had a significantly higher incidence of transient <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and elevations of serum creatinine (greater than or equal to 1.8 mg/dL) than did the neonates treated with placebo.</p>
<p>The incidences of <span class="product-label-link" type="condition" conceptid="373766" conceptname="Retinopathy of prematurity">retrolental fibroplasia</span> (grades III and IV) and <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span> in neonates treated with Indomethacin for Injection were no greater than in placebo controls and were statistically significantly lower than in surgically-treated neonates.</p>
<p>The following additional adverse reactions in neonates have been reported from the collaborative study, anecdotal case reports, from other studies using rectal, oral, or intravenous indomethacin for treatment of <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> or in marketed use.  The rates are calculated from a database that contains experience of 849 indomethacin-treated neonates reported in the medical literature, regardless of the route of administration.  One year follow-up is available on 175 neonates and shows no long-term sequelae that could be attributed to indomethacin.  In controlled clinical studies, only <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> and renal dysfunction (of the reactions listed below) occurred statistically significantly more frequently after Indomethacin for Injection than after placebo.  Reactions marked with a single asterisk (*) occurred in 3 to 9 percent of indomethacin-treated neonates; those marked with a double asterisk (**) occurred in 3 to 9 percent of both indomethacin- and placebo-treated neonates.  Unmarked reactions occurred in less than 3 percent of neonates.</p>
<p><span class="Italics"><span class="Emphasis">Renal:</span></span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction in 41 percent of neonates, including one or more of the following: reduced urinary output; reduced urine sodium, chloride, or potassium, urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>, free water clearance, or glomerular filtration rate; elevated serum creatinine or BUN; <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>.</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>**, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
<p><span class="Italics"><span class="Emphasis">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>*, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, transient <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4340781" conceptname="Perforation of stomach">gastric perforation</span>, localized perforation(s) of the small and/or large intestine, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.</p>
<p><span class="Italics"><span class="Emphasis">Metabolic:</span></span> <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>*, elevated serum potassium*, reduction in blood sugar, including <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, increased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>).</p>
<p><span class="Italics"><span class="Emphasis">Coagulation:</span></span> decreased platelet aggregation <span class="Italics"><span class="Emphasis">[see <a href="#ffb4d13c-2787-4213-95af-1a14dc8f2f7f"> Warnings and Precautions (5.3)</a>]</span></span>.</p>
<p>The following adverse reactions have also been reported in neonates treated with indomethacin, however, a causal relationship to therapy with Indomethacin for Injection has not been established:</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Italics"><span class="Emphasis">Respiratory:</span></span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, exacerbation of pre-existing pulmonary <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics"><span class="Emphasis">Metabolic:</span></span> <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>/<span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>.</p>
<p><span class="Italics"><span class="Emphasis">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics"><span class="Emphasis">Ophthalmic:</span></span> <span class="product-label-link" type="condition" conceptid="373766" conceptname="Retinopathy of prematurity">retrolental fibroplasia</span>.**</p>
<p>A variety of additional adverse experiences have been reported in adults treated with oral indomethacin for moderate to severe <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, acute painful shoulder and acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span> (see package insert for oral indomethacin for additional information concerning adverse reactions and other cautionary statements).  Their relevance to the pre-term infant receiving indomethacin for <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> is unknown, however, the possibility exists that these experiences may be associated with the use of Indomethacin for Injection in pre-term infants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="fd58e918-0001-443a-99bb-86e4286258fd"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">As renal function may be reduced by Indomethacin for Injection, consider reducing the dosage of those medications that rely on adequate renal function for their elimination.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="e2a3187c-6d3d-47c0-8e7f-7ad0d607bfa1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Digoxin<br>
</h2>
<p class="First">Because the half-life of digoxin (given frequently to pre-term infants with <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> and associated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>) may be prolonged when given concomitantly with indomethacin, observe neonates receiving concomitant digoxin closely; frequent ECGs and serum digoxin levels may be required to prevent or detect <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> early.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="c8db1e5f-72fb-4863-87ff-a96f9f0b421b"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Anticoagulants<br>
</h2>
<p class="First">Indomethacin usually does not influence the <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> produced by anticoagulants.  When indomethacin is added to anticoagulants, monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time closely.  In post-marketing experience, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in patients on concomitant treatment with anticoagulants and Indomethacin for Injection.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ae4bd8ca-ce50-4b5b-b145-7c760405d33b"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Furosemide<br>
</h2>
<p class="First">Therapy with indomethacin may blunt the natriuretic effect of furosemide.  This response has been attributed to inhibition of prostaglandin synthesis by non-steroidal anti-inflammatory drugs.  In a study of 19 premature infants with <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> treated with either Indomethacin for Injection alone or a combination of Indomethacin for Injection and furosemide, results showed that neonates receiving both Indomethacin for Injection and furosemide had significantly higher urinary output, higher levels of sodium and chloride excretion, and higher glomerular filtration rates than did those receiving Indomethacin for Injection alone.  In this study, therapy with furosemide helped to maintain renal function in the premature infant when Indomethacin for Injection was added.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="fc720934-60ca-408c-8ac1-b0f6698ba57a"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Aminoglycosides<br>
</h2>
<p class="First">In one study of premature infants treated with Indomethacin for Injection and also receiving either gentamicin or amikacin, both peak and trough levels of these aminoglycosides were significantly elevated.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="b2282bea-2b1a-4ab2-b6bc-1f9e2ea97815"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Drugs that Act on the Renin-Angiotensin System<br>
</h2>
<p class="First">In some patients with compromised renal function, the co-administration of an NSAID and an ACE inhibitor or angiotensin II antagonist may result in further deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, which is usually reversible.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a341c655-4f0f-497f-b193-4cea1fd3f666"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Sterile Indomethacin for Injection for intravenous administration is lyophilized indomethacin for injection.  Each vial of indomethacin for injection contains 1 mg indomethacin; 0.29 mg monobasic sodium phosphate, 0.41 mg dibasic sodium phosphate and not more than 0.24 mg of sodium hydroxide (used for converting indomethacin base to the sodium salt) as a white to yellow lyophilized powder or plug.  Variations in the size of the lyophilized plug and the intensity of color have no relationship to the quality or amount of indomethacin present in the vial.</p>
<p>The reconstituted solution, pH 6.0 to 7.5, is clear, slightly yellow and essentially free from visible particles.  The pH of the product does not meet the USP monograph [FD&amp;C Act Chapter V, SEC. 501. [21USC §351](b)].</p>
<p>Indomethacin is designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1<span class="Italics"><span class="Emphasis">H</span></span>-indole-3-acetic acid.  The structural formula is:</p>
<p> <img alt="stru" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e38747-c553-4e2d-bc23-634e1dd90b8d&amp;name=indomethacin-for-injection-figure-1-indo-stru.jpg"></p>
<p>  <span class="Bold"><span class="Emphasis">C<span class="Sub">19</span>H<span class="Sub">16</span>ClNO<span class="Sub">4                  </span></span></span>                        <span class="Bold"><span class="Emphasis">M.W. 357.8</span></span> </p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="bf51d17d-5cb9-46a0-a165-01751b0f0d3d"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="bb22b3f0-a15c-4e4a-bb6e-745cb4c2aac2"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Although the exact mechanism of action through which indomethacin causes closure of a <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> is not known, it is believed to be through inhibition of prostaglandin synthesis.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="e7dd912b-9bb9-4ec4-8d28-bd0deaea9977"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Indomethacin has been shown to be a potent inhibitor of prostaglandin synthesis, both <span class="Italics"><span class="Emphasis">in vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span>.  In human newborns with certain congenital heart malformations, PGE 1 dilates the ductus arteriosus.  In fetal and newborn lambs, E type prostaglandins have also been shown to maintain the patency of the ductus, and as in human newborns, indomethacin causes its constriction.</p>
<p>Studies in healthy young animals and in premature infants with <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> indicated that, after the first dose of intravenous indomethacin, there was a transient reduction in cerebral blood flow velocity and cerebral blood flow.  Similar decreases in mesenteric blood flow and velocity have been observed.  The clinical significance of these effects has not been established.</p>
<p>In double-blind, placebo-controlled studies of Indomethacin for Injection in 460 small pre-term infants, weighing 1,750 g or less, the neonates treated with placebo had a ductus closure rate after 48 hours of 25 to 30 percent, whereas those treated with Indomethacin for Injection had a 75 to 80 percent closure rate.  In one of these studies, a multicenter study, involving 405 pre-term infants, later reopening of the ductus arteriosus occurred in 26 percent of neonates treated with Indomethacin for Injection however, 70 percent of these closed subsequently without the need for surgery or additional indomethacin.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="b2031a3c-cfe1-4d89-be43-f77cebe8ef4a"></a><a name="section-9.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The disposition of indomethacin following intravenous administration (0.2 mg/kg) in pre-term neonates with <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> has not been extensively evaluated.  Even though the plasma half-life of indomethacin was variable among premature infants, it was shown to vary inversely with postnatal age and weight.  In one study, of 28 neonates who could be evaluated, the plasma half-life in those less than 7 days old averaged 20 hours (range: 3 to 60 hours, n=18).  In neonates older than 7 days, the mean plasma half-life of indomethacin was 12 hours (range: 4 to 38 hours, n=10).  Grouping the neonates by weight, mean plasma half-life in those weighing less than 1,000 g was 21 hours (range: 9 to 60 hours, n=10); in those neonates weighing more than 1,000 g, the mean plasma half-life was 15 hours (range: 3 to 52 hours, n=18).</p>
<p>Following intravenous administration in adults, indomethacin is eliminated via renal excretion, metabolism, and biliary excretion.  Indomethacin undergoes appreciable enterohepatic circulation.  The mean plasma half-life of indomethacin is 4.5 hours.  In the absence of enterohepatic circulation, it is 90 minutes.  Indomethacin has been found to cross the blood-brain barrier and the placenta.</p>
<p>In adults, about 99 percent of indomethacin is bound to protein in plasma over the expected range of therapeutic plasma concentrations.  The percent bound in neonates has not been studied.  In controlled trials in premature infants, however, no evidence of bilirubin displacement has been observed as evidenced by increased incidence of bilirubin <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (<span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="a0fd4366-9620-47f8-aada-c18b90eb2620"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<p class="First">In rats and mice, oral indomethacin 4 mg/kg/day given during the last three days of gestation caused a decrease in maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and some maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>.  An increased incidence of neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in the diencephalon in the live-born fetuses was observed.  At 2 mg/kg/day, no increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> was observed as compared to the control groups.  Administration of 0.5 or 4 mg/kg/day during the first three days of life did not cause an increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at either dose level.</p>
<p>Pregnant rats, given 2 mg/kg/day and 4 mg/kg/day during the last trimester of gestation, delivered offspring whose pulmonary blood vessels were both reduced in number and excessively muscularized.  These findings are similar to those observed in the syndrome of persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the neonate.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f19bee57-58bc-4299-9536-25738cc1e7e2"></a><a name="section-11"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="f2870cbf-46f0-47c3-baaa-72bea18fc178"></a><a name="section-11.1"></a><p></p>
<h2>16.1 How Supplied<br>
</h2>
<p class="First">Sterile Indomethacin for Injection is a lyophilized white to yellow powder or plug supplied as single dose vials containing indomethacin for injection, equivalent to 1 mg indomethacin.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><br></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">NP605903</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-659-09</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Packaged individually.</p></td>
</tr>
</tbody></table>
<p>This container closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f6c94104-39d0-481f-82dd-1b2c1e2a0488"></a><a name="section-11.2"></a><p></p>
<h2>16.2 Storage<br>
</h2>
<p class="First">Store at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F).   Protect from light.  Store container in carton until contents have been used.</p>
<p>N+ and NOVAPLUS are registered trademarks of Novation, LLC.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="df5b3a09-3564-4d07-b67f-61a5c83a3a20"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:</p>
<p>Fresenius Kabi USA, LLC </p>
<p>Lake Zurich, IL 60047</p>
<p> </p>
<p>451358</p>
<p>Issued: November 2013</p>
<p><img alt="novaplus" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e38747-c553-4e2d-bc23-634e1dd90b8d&amp;name=indomethacin-for-injection-figure-2-novapluslogo.jpg"> </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="df9a5394-d8e8-43f9-bf41-30e7fd2fbc24"></a><a name="section-13"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Indomethacin for Injection 1 mg Vial Label</span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-659-09</p>
<p>NP605903</p>
<p><span class="Bold"><span class="Emphasis">INDOMETHACIN FOR INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">1 mg/vial</span></span></p>
<p>FOR THE PREPARATION OF INTRAVENOUS SOLUTIONS</p>
<p>Sterile     Rx only</p>
<p>Single Dose Vial - Discard unused portion</p>
<p><img alt="np vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e38747-c553-4e2d-bc23-634e1dd90b8d&amp;name=indomethacin-for-injection-figure-3-np605903-vial.jpg"> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Indomethacin for Injection 1 mg Carton Panel</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-659-09</p>
<p>NP605903</p>
<p><span class="Bold"><span class="Emphasis">INDOMETHACIN FOR INJECTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">1 mg/vial</span></span></p>
<p>For Intravenous Use Only<span class="Bold"><span class="Emphasis"> <br></span></span></p>
<p>FOR THE PREPARATION OF INTRAVENOUS SOLUTIONS</p>
<p>Rx only</p>
<p>One vial </p>
<p>Single Dose Vial - Discard any unused portion immediately.</p>
<p><img alt="np carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=30e38747-c553-4e2d-bc23-634e1dd90b8d&amp;name=indomethacin-for-injection-figure-4-np605903-carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INDOMETHACIN 		
					</strong><br><span class="contentTableReg">indomethacin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-659</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INDOMETHACIN</strong> (INDOMETHACIN) </td>
<td class="formItem">INDOMETHACIN</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem">0.29 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">0.41 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-659-09</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022536</td>
<td class="formItem">03/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-659)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>34827ccd-d510-4d30-9f1d-ff6871dd7f33</div>
<div>Set id: 30e38747-c553-4e2d-bc23-634e1dd90b8d</div>
<div>Version: 2</div>
<div>Effective Time: 20140429</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
